Study on the expression and clinical prognostic value of DOT1L and STAT5B in renal clear cell carcinoma tissue
Wang Wenqiang
Feng Shaopeng
Gao Bingzhang
Yan Xiaochen
Wu Yanghui
Abstract：Objective To investigate the expression and clinical prognostic value of Telomere Silencing Disruptor 1(DOT1L),Transcription Signal Transducer and activator 5B(STAT5B)in renal clear cell carcinoma(ccRCC).Methods One hundred and four patients with ccRCC who underwent surgical treatment in our hospital from March 2019 to April 2021 were selected.Real time fluorescence quantitative PCR and immunohistochemistry were used to detect the mRNA and protein ex-pression levels of DOT1L and STAT5B in ccRCC cancer tissues and adjacent tissues.The correlation between DOT1L mR-NA and STAT5B mRNA were analyzed by Pearson correlation analysis.Kaplan Meier curve analysis was used to analyze the impact of DOT1L and STAT5B expression on progression free survival prognosis in ccRCC patients.The factors affect-ing the prognosis of progression free survival in ccRCC was analyzed by multifactorial Cox regression model.Results the expression levels of DOT1L mRNA and STAT5B mRNA in ccRCC cancer tissues were higher than those in adjacent tissues,and the differences were statistically significant(t=40.071,45.067,P＜0.001).The expression levels of DOT1L mRNA and STAT5B mRNA in ccRCC cancer tissues were positively correlated(r=0.726,P＜0.001).The positivity rates ofDOT1Lpro-tein and STAT5B protein in ccRCC cancer tissues were 69.23％,67.31％,higher than those in adjacent tissues 5.77％,7.69％(t=89.354,78.851,P＜0.001).The positivity rates of DOT1L protein and STAT5B protein in ccRCC cancer tissues with TNM stage Ⅲ and Fuhrman grade Ⅲ-Ⅳ were higher than those with TNM stage Ⅰ-Ⅱ and Fuhrman grade Ⅰ-Ⅱ,and the differences were statistically significant(x2=19.492/＜0.001,10.963/0.001;10.316/0.001,17.148/＜0.001).The 3-year progres-sion free survival rate of the DOT1L positive and negative groups was 70.83％(51/72),lower than the negative group's 87.50％(28/32)(Log rank x2=4.136,P=0.030);the 3-year progression free survival rate of the STAT5B positive group was 68.57％(48/70),lower than the negative group's 91.18％(31/34)(Log rank x2=5.339,P=0.021).Fuhrman grading Ⅲ-Ⅳ,TNM stage Ⅲ,DOT1L positivity,and STAT5B positivity were risk factors affecting the prognosis of ccRCC progression free survival[HR(95％CI)=1.586(1.024-2.455),2.016(1.341-3.030),1.423(1.168-1.735),1.436(1.158-1.782)].Con-clusion The upregulation of DOT1L and STAT5B expression in cancer tissues of ccRCC patients synergistically promotes the progression of ccRCC and is a new indicator for evaluating the prognosis of progression free survival in patients.
Keywords：Renal clear cell carcinomaTelomere silencing disruptor 1Transcription signal transducer and activator 5BSurvival prognosis without progression
Publication Date：2025-03-18
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：5( 359-363 )